{"protocolSection":{"identificationModule":{"nctId":"NCT04408755","orgStudyIdInfo":{"id":"20-AVP-786-306"},"secondaryIdInfos":[{"id":"2020-000798-26","type":"EUDRACT_NUMBER"},{"id":"2023-504990-19-00","type":"CTIS"}],"organization":{"fullName":"Otsuka Pharmaceutical Development & Commercialization, Inc.","class":"INDUSTRY"},"briefTitle":"Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type"},"statusModule":{"statusVerifiedDate":"2025-05","overallStatus":"TERMINATED","whyStopped":"The AVP-786 program was discontinued, the recruitment was stopped and all participants are no longer being examined or receiving intervention.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-07-13","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-06-27","type":"ACTUAL"},"completionDateStruct":{"date":"2024-06-27","type":"ACTUAL"},"studyFirstSubmitDate":"2020-05-26","studyFirstSubmitQcDate":"2020-05-26","studyFirstPostDateStruct":{"date":"2020-05-29","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-04-04","resultsFirstSubmitQcDate":"2025-05-12","resultsFirstPostDateStruct":{"date":"2025-05-30","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-05-12","lastUpdatePostDateStruct":{"date":"2025-05-30","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study was conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide \\[d6-DM\\]/quinidine sulfate \\[Q\\]) compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.","detailedDescription":"Eligible participants for this study had a diagnosis of probable Alzheimer's disease (AD) and had clinically significant, moderate/severe agitation secondary to AD.\n\nThis was a multicenter, randomized, double-blind, placebo-controlled study, consisting of 12 weeks of treatment. Screening occurred within 4 weeks prior to randomization. Following screening procedures for assessment of inclusion and exclusion criteria, eligible participants were randomized into the study.\n\n184 participants were enrolled into the study.\n\nStudy medication was administered orally twice daily from Day 1 through Day 85."},"conditionsModule":{"conditions":["Agitation in Patients With Dementia of the Alzheimer's Type"],"keywords":["Agitation","Dementia of the Alzheimer's type","Alzheimer's disease","AVP-786","Deudextromethorphan hydrobromide","Quinidine sulfate"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":184,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants who were enrolled in 1-week double-blind placebo lead-in Period A, were then randomized to receive AVP-786 matching placebo capsules, twice a day, for 11 weeks in Period B.","interventionNames":["Drug: Placebo"]},{"label":"AVP-786-18","type":"EXPERIMENTAL","description":"Participants who were enrolled in 1-week double-blind placebo lead-in Period A, were then randomized to receive AVP-786-18 (d6-DM 18 milligrams (mg)/Q 4.9 mg) capsules, twice a day, for 11 weeks in Period B.","interventionNames":["Drug: AVP-786"]},{"label":"AVP-786-42.63","type":"EXPERIMENTAL","description":"Participants who were enrolled in 1-week double-blind placebo lead-in Period A, were then randomized to receive AVP-786-42.63 (d6-DM 42.63 mg/Q 4.9 mg) capsules, twice a day, for 11 weeks in Period B.","interventionNames":["Drug: AVP-786"]}],"interventions":[{"type":"DRUG","name":"AVP-786","description":"oral capsules","armGroupLabels":["AVP-786-18","AVP-786-42.63"]},{"type":"DRUG","name":"Placebo","description":"oral capsules","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From the End of Period A (Week 1) to Week 10 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score","description":"The CMAI is used to assess the frequency of manifestations of agitated behaviors in elderly persons. It consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. These distinct agitation syndromes include aggressive behavior, physically nonaggressive behavior, and verbally agitated behavior. Each of the 29 items is rated on a 7-point scale of frequency (1 = never, 2 = less than once a week but still occurring, 3 = once or twice a week, 4 = several times a week, 5 = once or twice a day, 6 = several times a day, 7 = several times an hour). The ratings are based on the 2 weeks preceding assessment of the CMAI. Higher scores indicate higher frequency of agitated behaviours while lower scores indicate lower frequency of agitated behaviours.","timeFrame":"Week 1 to Week 10"},{"measure":"Number of Participants With Treatment Emergent Adverse Events (TEAE) and Serious TEAE","description":"An adverse event (AE) is any untoward medical occurrence or unintended change (eg, physical, psychological, or behavioral), including inter-current illness, that does not necessarily have a causal relationship with the study treatment. A serious adverse event (SAE) is any AE occurring at any dose that results in death, life-threatening experience, persistent or significant disability/incapacity, in-patient hospitalization or prolongation of hospitalization or congenital anomaly/birth defect. TEAEs are all AEs (including serious and non-serious) which started after start of double-blind study drug treatment; or if the event was continuous from baseline and was worsening, serious, study drug related, or resulted in death, discontinuation, interruption or reduction of study therapy.","timeFrame":"From randomization (Week 2) up to 30 days after last dose of study drug (Up to Week 16)"}],"secondaryOutcomes":[{"measure":"Change From the End of Period A (Week 1) to Week 10 in the Clinical Global Impression of Severity of Illness (CGIS) Score, as Related to Agitation","description":"The CGIS is an observer-rated scale that measures illness severity. The CGIS-Agitation is a 7-point (1-7) scale (1 = normal, not at all ill; 7 = among the most extremely ill patients) and assesses severity of agitation in this study. Higher scores indicate severe agitation while the lower scores indicate little or no agitation.","timeFrame":"Week 1 to Week 10"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants with a diagnosis of probable Alzheimer's disease according to the 2011 Neuropsychiatric Inventory Agitation/Aggression (NPI-AA) working groups criteria\n* Participants with clinically significant, moderate-to-severe agitation for at least 2 weeks prior to Screening that interferes with daily routine per the Investigator's judgment\n* Participants who require pharmacotherapy for the treatment of agitation per the Investigator's judgment after an evaluation of reversible factors and a course of nonpharmacological interventions\n* Diagnosis of agitation must meet the International Psychogeriatric Association (IPA) provisional definition of agitation.\n* Participants meeting an additional predetermined blinded eligibility criterion, which will remain blinded to the clinical study site Investigators and staff\n* Participants with a reliable caregiver who is able and willing to comply with all study procedures, including adherence to administering study drug and not administering any prohibited medications during the course of the study, and who spends a minimum of 2 hours per day for 4 days per week with the participant\n\nExclusion Criteria:\n\n* Participants with dementia predominantly of the non-Alzheimer's type (e.g., vascular dementia, frontotemporal dementia, Parkinson's disease, substance-induced dementia)\n* Participants with symptoms of agitation that are not secondary to Alzheimer's dementia (e.g., secondary to pain, other psychiatric disorder, or delirium)\n* Participants with co-existent clinically significant or unstable systemic diseases that could confound the interpretation of the safety results of the study (e.g., malignancy \\[except skin basal-cell carcinoma\\], poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, or unstable valvular heart disease)\n* Participants with myasthenia gravis","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Clinical Research Site #840-081","city":"Fort Smith","state":"Arkansas","zip":"72901","country":"United States","geoPoint":{"lat":35.38592,"lon":-94.39855}},{"facility":"Clinical Research Site #840-035","city":"La Jolla","state":"California","zip":"92093","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"Clinical Research Site #840-084","city":"Los Angeles","state":"California","zip":"70072","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Clinical Research Site #840-050","city":"Oceanside","state":"California","zip":"92056","country":"United States","geoPoint":{"lat":33.19587,"lon":-117.37948}},{"facility":"Clinical Research Site #840-064","city":"Pasadena","state":"California","zip":"91105","country":"United States","geoPoint":{"lat":34.14778,"lon":-118.14452}},{"facility":"Clinical Research Site #840-098","city":"Santa Ana","state":"California","zip":"92705","country":"United States","geoPoint":{"lat":33.74557,"lon":-117.86783}},{"facility":"Clinical Research Site #840-090","city":"Basalt","state":"Colorado","zip":"81621","country":"United States","geoPoint":{"lat":39.36887,"lon":-107.03282}},{"facility":"Clinical Research Site #840-009","city":"Atlantis","state":"Florida","zip":"33462","country":"United States","geoPoint":{"lat":26.5909,"lon":-80.10088}},{"facility":"Clinical Research Site #840-056","city":"Brandon","state":"Florida","zip":"33511","country":"United States","geoPoint":{"lat":27.9378,"lon":-82.28592}},{"facility":"Clinical Research Site #840-020","city":"Coral Gables","state":"Florida","zip":"33134","country":"United States","geoPoint":{"lat":25.72149,"lon":-80.26838}},{"facility":"Clinical Research Site #840-059","city":"Doral","state":"Florida","zip":"33166","country":"United States","geoPoint":{"lat":25.81954,"lon":-80.35533}},{"facility":"Clinical Research Site #840-131","city":"Hialeah","state":"Florida","zip":"33012","country":"United States","geoPoint":{"lat":25.8576,"lon":-80.27811}},{"facility":"Clinical Research Site #840-039","city":"Jacksonville","state":"Florida","zip":"32256","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Clinical Research Site #840-012","city":"Kissimmee","state":"Florida","zip":"34744","country":"United States","geoPoint":{"lat":28.30468,"lon":-81.41667}},{"facility":"Clinical Research Site #840-069","city":"Maitland","state":"Florida","zip":"32751","country":"United States","geoPoint":{"lat":28.62778,"lon":-81.36312}},{"facility":"Clinical Research Site #840-083","city":"Maitland","state":"Florida","zip":"32751","country":"United States","geoPoint":{"lat":28.62778,"lon":-81.36312}},{"facility":"Clinical Research Site #840-118","city":"Miami","state":"Florida","zip":"33032","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Clinical Research Site #840-004","city":"Miami","state":"Florida","zip":"33126","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Clinical Research Site #840-125","city":"Miami","state":"Florida","zip":"33126","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Clinical Research Site #840-104","city":"Miami","state":"Florida","zip":"33144","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Clinical Research Site #840-133","city":"Miami","state":"Florida","zip":"33165","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Clinical Research Site #840-042","city":"Miami","state":"Florida","zip":"33175","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Clinical Research Site #840-003","city":"Miami","state":"Florida","zip":"33467","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Clinical Research Site #840-036","city":"Orlando","state":"Florida","zip":"32819","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Clinical Research Site 840-111","city":"Pembroke Pines","state":"Florida","zip":"33024","country":"United States","geoPoint":{"lat":26.00315,"lon":-80.22394}},{"facility":"Clinical Research Site #840-096","city":"Pensacola","state":"Florida","zip":"32503","country":"United States","geoPoint":{"lat":30.42131,"lon":-87.21691}},{"facility":"Clinical Research Site","city":"Pompano Beach","state":"Florida","zip":"33064","country":"United States","geoPoint":{"lat":26.23786,"lon":-80.12477}},{"facility":"Clinical Research Site #840-079","city":"Tampa","state":"Florida","zip":"33614","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Clinical Research Site #840-112","city":"Tampa","state":"Florida","zip":"33615","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Clinical Research Site #840-046","city":"Tampa","state":"Florida","zip":"33634","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Clinical Research Site #840-107","city":"West Palm Beach","state":"Florida","zip":"33407","country":"United States","geoPoint":{"lat":26.71534,"lon":-80.05337}},{"facility":"Clinical Research Site #840-049","city":"Glen Burnie","state":"Maryland","zip":"21061","country":"United States","geoPoint":{"lat":39.16261,"lon":-76.62469}},{"facility":"Clinical Research Site #840-093","city":"Rochester Hills","state":"Michigan","zip":"48307","country":"United States","geoPoint":{"lat":42.65837,"lon":-83.14993}},{"facility":"Clinical Research Site #840-015","city":"Hattiesburg","state":"Mississippi","zip":"39401","country":"United States","geoPoint":{"lat":31.32712,"lon":-89.29034}},{"facility":"Clinical Research Site #840-029","city":"West Long Branch","state":"New Jersey","zip":"07764","country":"United States","geoPoint":{"lat":40.29039,"lon":-74.01764}},{"facility":"Clinical Research Site #840-097","city":"Bronx","state":"New York","zip":"10466","country":"United States","geoPoint":{"lat":40.84985,"lon":-73.86641}},{"facility":"Clinical Research Site #840-072","city":"New Windsor","state":"New York","zip":"12553","country":"United States","geoPoint":{"lat":41.47676,"lon":-74.02375}},{"facility":"Clinical Research Site #840-095","city":"Monroe","state":"North Carolina","zip":"28112","country":"United States","geoPoint":{"lat":34.98543,"lon":-80.54951}},{"facility":"Clinical Research Site #840-060","city":"Canton","state":"Ohio","zip":"44718","country":"United States","geoPoint":{"lat":40.79895,"lon":-81.37845}},{"facility":"Clinical Research Site #840-028","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Clinical Research Site #840-061","city":"Edmond","state":"Oklahoma","zip":"73012","country":"United States","geoPoint":{"lat":35.65283,"lon":-97.4781}},{"facility":"Clinical Research Site #840-099","city":"Tulsa","state":"Oklahoma","zip":"74136","country":"United States","geoPoint":{"lat":36.15398,"lon":-95.99277}},{"facility":"Clinical Research Site #840-115","city":"McKinney","state":"Texas","zip":"75069","country":"United States","geoPoint":{"lat":33.19762,"lon":-96.61527}},{"facility":"Clinical Research Site","city":"The Woodlands","state":"Texas","zip":"77381","country":"United States","geoPoint":{"lat":30.15799,"lon":-95.48938}},{"facility":"Clinical Research Site #840-025","city":"Richmond","state":"Virginia","zip":"23236","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"Clinical Research Site #100-115","city":"Pernik","zip":"2300","country":"Bulgaria","geoPoint":{"lat":42.6,"lon":23.03333}},{"facility":"Clinical Research Site #100-112","city":"Pleven","zip":"5800","country":"Bulgaria","geoPoint":{"lat":43.41667,"lon":24.61667}},{"facility":"Clinical Research Site #100-106","city":"Plovdiv","zip":"4002","country":"Bulgaria","geoPoint":{"lat":42.15,"lon":24.75}},{"facility":"Clinical Research Site #100-102","city":"Sofia","zip":"1408","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"Clinical Research Site #100-111","city":"Sofia","zip":"1408","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"Clinical Research Site #100-105","city":"Varna","zip":"9020","country":"Bulgaria","geoPoint":{"lat":43.21667,"lon":27.91667}},{"facility":"Clinical Research Site #100-108","city":"Varna","zip":"9020","country":"Bulgaria","geoPoint":{"lat":43.21667,"lon":27.91667}},{"facility":"Clinical Research Site #100-113","city":"Veliko Tarnovo","zip":"5006","country":"Bulgaria","geoPoint":{"lat":43.08124,"lon":25.62904}},{"facility":"Clinical Research Site # 208-001","city":"Aalborg","state":"Region Nordjylland","zip":"9000","country":"Denmark","geoPoint":{"lat":57.048,"lon":9.9187}},{"facility":"Clinical Research Site #208-002","city":"Aalborg","zip":"9000","country":"Denmark","geoPoint":{"lat":57.048,"lon":9.9187}},{"facility":"Clinical Research Site #1 Site #233-002","city":"Tallinn","zip":"11315","country":"Estonia","geoPoint":{"lat":59.43696,"lon":24.75353}},{"facility":"Clinical Research Site #2 Site #233-004","city":"Tallinn","zip":"11315","country":"Estonia","geoPoint":{"lat":59.43696,"lon":24.75353}},{"facility":"Clinical Research Site #233-001","city":"Tartu","zip":"50406","country":"Estonia","geoPoint":{"lat":58.38062,"lon":26.72509}},{"facility":"Clinical Research Site #276-017","city":"Böblingen","state":"Baden-Württemberg","zip":"71034","country":"Germany","geoPoint":{"lat":48.68212,"lon":9.01171}},{"facility":"Clinical Research Site #276-005","city":"Bad Homburg Vor Der Höhe","state":"Hessen","zip":"61348","country":"Germany","geoPoint":{"lat":50.22683,"lon":8.61816}},{"facility":"Clinical Research Site #276-012","city":"Gera","state":"Thüringen","zip":"935","country":"Germany","geoPoint":{"lat":50.88029,"lon":12.08187}},{"facility":"Clinical Research Site 276-014","city":"Berlin","zip":"13187","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Clinical Research Site# 300-005","city":"Athens","zip":"15125","country":"Greece","geoPoint":{"lat":37.97945,"lon":23.71622}},{"facility":"Clinical Research Site #300-006","city":"Ioannina","zip":"45500","country":"Greece","geoPoint":{"lat":39.66486,"lon":20.85189}},{"facility":"Clinical Research Site #300-003","city":"Thessaloníki","zip":"54645","country":"Greece","geoPoint":{"lat":40.64361,"lon":22.93086}},{"facility":"Clinical Research Site #616-018","city":"Zabrze","state":"Katowice","zip":"41-807","country":"Poland","geoPoint":{"lat":50.32492,"lon":18.78576}},{"facility":"Clinical Research Site #616-009","city":"Bydgoszcz","state":"Kujawsko-Pomorskie","zip":"85-023","country":"Poland","geoPoint":{"lat":53.1235,"lon":18.00762}},{"facility":"Clinical Research Site #616-006","city":"Lublin","state":"Lubelskie","zip":"20-093","country":"Poland","geoPoint":{"lat":51.25,"lon":22.56667}},{"facility":"Clinical Research Site #616-015","city":"Sochaczew","state":"Mazowieckie","zip":"96-500","country":"Poland","geoPoint":{"lat":52.22944,"lon":20.23838}},{"facility":"Clinical Research Site #616-013","city":"Bydgoszcz","zip":"85-163","country":"Poland","geoPoint":{"lat":53.1235,"lon":18.00762}},{"facility":"Clinical Research Site #616-004","city":"Kielce","zip":"25-411","country":"Poland","geoPoint":{"lat":50.87033,"lon":20.62752}},{"facility":"Clinical Research Site #616-008","city":"Lublin","zip":"20-064","country":"Poland","geoPoint":{"lat":51.25,"lon":22.56667}},{"facility":"Clinical Research Site #616-010","city":"Lublin","zip":"20-080","country":"Poland","geoPoint":{"lat":51.25,"lon":22.56667}},{"facility":"Clinical Research Site #616-012","city":"Poznan","zip":"60-369","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"Clinical Research Site #616-005","city":"Poznan","zip":"61-853","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"Clinical Research Site #616-001","city":"Pruszcz Gdanski","zip":"83-000","country":"Poland","geoPoint":{"lat":54.26217,"lon":18.63625}},{"facility":"Clinical Research Site #616-007","city":"Warszawa","zip":"01-737","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Clinical Research Site #620-007","city":"Guimarães","state":"Braga","zip":"4835-044","country":"Portugal","geoPoint":{"lat":41.44443,"lon":-8.29619}},{"facility":"Clinical Research Site #620-004","city":"Braga","zip":"4710-243","country":"Portugal","geoPoint":{"lat":41.55032,"lon":-8.42005}},{"facility":"Clinical Research Site #620-005","city":"Coimbra","zip":"3000-075","country":"Portugal","geoPoint":{"lat":40.20564,"lon":-8.41955}},{"facility":"Clinical Research Site #620-002","city":"Torres Vedras","zip":"2560-280","country":"Portugal","geoPoint":{"lat":39.09109,"lon":-9.2586}},{"facility":"Clinical Research Site #630-001","city":"Bayamon","zip":"00961","country":"Puerto Rico","geoPoint":{"lat":18.39856,"lon":-66.15572}},{"facility":"Clinical Research Site #630-003","city":"Rio Piedras","zip":"00935","country":"Puerto Rico","geoPoint":{"lat":18.39745,"lon":-66.04989}},{"facility":"Clinical Research Site #630-002","city":"San Juan","zip":"00918","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}},{"facility":"Clinical Research Site #630-005","city":"San Juan","zip":"926","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}},{"facility":"Clinical Research Site #804-006","city":"Dnipro","zip":"49005","country":"Ukraine","geoPoint":{"lat":48.4593,"lon":35.03864}},{"facility":"Clinical Research Site #804-003","city":"Kharkiv","zip":"61068","country":"Ukraine","geoPoint":{"lat":49.98081,"lon":36.25272}},{"facility":"Clinical Research Site #804-004","city":"Kiev","zip":"8631","country":"Ukraine","geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Clinical Research Site #804-005","city":"Kyiv","zip":"04080","country":"Ukraine","geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Clinical Research Site #804-007","city":"Lviv","zip":"79021","country":"Ukraine","geoPoint":{"lat":49.83826,"lon":24.02324}},{"facility":"Clinical Research Site #826-003","city":"Blandford Forum","zip":"DT11 7DD","country":"United Kingdom","geoPoint":{"lat":50.86073,"lon":-2.16174}},{"facility":"Clinical Research Site #826-004","city":"Crowborough","zip":"TN61NY","country":"United Kingdom","geoPoint":{"lat":51.06098,"lon":0.16342}},{"facility":"Clinical Research Site #826-001","city":"Fulwood","zip":"PR2 9HT","country":"United Kingdom","geoPoint":{"lat":53.35,"lon":-1.55}},{"facility":"Clinical Research Site# 826-006","city":"Manchester","zip":"M25 3BL","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}},{"facility":"Clinical Research Site #826-002","city":"Motherwell","zip":"ML1 4UF","country":"United Kingdom","geoPoint":{"lat":55.78924,"lon":-3.99187}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"Data will be available after marketing approval in global markets or beginning 1-3 years following article publication. There is no end date to the availability of the data.","accessCriteria":"Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/","url":"https://clinical-trials.otsuka.com"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 530 participants were screened for the study, of which 184 participants were enrolled and treated with placebo in a 1-week double-blind placebo lead-in period (Period A). A total of 173 participants were then randomized to receive AVP-786 (deudextromethorphan hydrobromide \\[d6-DM\\]/quinidine sulfate \\[Q\\])-18, AVP-786-42.63 or placebo in the 11-week randomization period (Period B).","recruitmentDetails":"Participants took part in the study at clinical sites in the North America and Europe from 13 July 2020 to 27 June 2024.","groups":[{"id":"FG000","title":"All Enrolled","description":"Participants received AVP-786 matching placebo capsules, twice a day, for 1 week in Period A."},{"id":"FG001","title":"Placebo","description":"Participants who were enrolled in 1-week double-blind placebo lead-in Period A, were then randomized to receive AVP-786 matching placebo capsules, twice a day, for 11 weeks in Period B."},{"id":"FG002","title":"AVP-786-18","description":"Participants who were enrolled in 1-week double-blind placebo lead-in Period A, were then randomized to receive AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) capsules, twice a day, for 11 weeks in Period B."},{"id":"FG003","title":"AVP-786-42.63","description":"Participants who were enrolled in 1-week double-blind placebo lead-in Period A, were then randomized to receive AVP-786-42.63 (d6-DM 42.63 mg/Q 4.9 mg) capsules, twice a day, for 11 weeks in Period B."}],"periods":[{"title":"Period A (Placebo lead-in)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"184"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"173"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]}]},{"title":"Period B (Randomization Period)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"173 Participants who completed Period A, were randomized to Period B to receive Placebo, AVP-786-18, and AVP-786-42.63.","numSubjects":"0"},{"groupId":"FG001","comment":"Out of 173 participants who completed Period A, 56 were randomized to receive matching Placebo.","numSubjects":"56"},{"groupId":"FG002","comment":"Out of 173 participants who completed Period A, 60 were randomized to receive AVP-786-18 in Period B.","numSubjects":"60"},{"groupId":"FG003","comment":"Out of 173 participants who completed Period A, 57 were randomized to receive AVP-786-42.63 in Period B.","numSubjects":"57"}]},{"type":"Safety Population","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"56"},{"groupId":"FG002","numSubjects":"60"},{"groupId":"FG003","numSubjects":"57"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"44"},{"groupId":"FG002","numSubjects":"48"},{"groupId":"FG003","numSubjects":"48"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"9"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Protocol Deviation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Study Subject Withdrawal by Parent or Guardian","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"2"}]},{"type":"Study Terminated by Sponsor","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"3"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Reason not Specified","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Randomized population included all participants who were randomized in the double-blind period B of the study.","groups":[{"id":"BG000","title":"Placebo","description":"Participants were enrolled in 1-week double-blind placebo lead-in Period A, and were then randomized to receive AVP-786 matching placebo capsules, twice a day, for 11 weeks in Period B."},{"id":"BG001","title":"AVP-786-18","description":"Participants were enrolled in 1-week double-blind placebo lead-in Period A, and were then randomized to receive AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) capsules, twice a day, for 11 weeks in Period B."},{"id":"BG002","title":"AVP-786-42.63","description":"Participants were enrolled in 1-week double-blind placebo lead-in Period A, and were then randomized to receive AVP-786-42.63 (d6-DM 42.63 mg/Q 4.9 mg) capsules, twice a day, for 11 weeks in Period B."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"57"},{"groupId":"BG003","value":"173"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"76.5","spread":"7.52"},{"groupId":"BG001","value":"73.9","spread":"7.85"},{"groupId":"BG002","value":"74.8","spread":"6.47"},{"groupId":"BG003","value":"75.0","spread":"7.35"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"33"},{"groupId":"BG003","value":"111"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"62"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"14"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"50"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"53"},{"groupId":"BG003","value":"158"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Ethnicity","categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"36"},{"groupId":"BG003","value":"107"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"61"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"5"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From the End of Period A (Week 1) to Week 10 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score","description":"The CMAI is used to assess the frequency of manifestations of agitated behaviors in elderly persons. It consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. These distinct agitation syndromes include aggressive behavior, physically nonaggressive behavior, and verbally agitated behavior. Each of the 29 items is rated on a 7-point scale of frequency (1 = never, 2 = less than once a week but still occurring, 3 = once or twice a week, 4 = several times a week, 5 = once or twice a day, 6 = several times a day, 7 = several times an hour). The ratings are based on the 2 weeks preceding assessment of the CMAI. Higher scores indicate higher frequency of agitated behaviours while lower scores indicate lower frequency of agitated behaviours.","populationDescription":"Due to discontinuation of development of the AVP-786 compound, no data was collected and analyzed as planned for this pre-specified primary efficacy outcome measure as noted in the SAP. Only safety data was collected and analyzed.","reportingStatus":"POSTED","timeFrame":"Week 1 to Week 10","groups":[{"id":"OG000","title":"Placebo","description":"Participants were enrolled in 1-week double-blind placebo lead-in Period A, and were then randomized to receive AVP-786 matching placebo capsules, twice a day, for 11 weeks in Period B."},{"id":"OG001","title":"AVP-786-18","description":"Participants were enrolled in 1-week double-blind placebo lead-in Period A, and were then randomized to receive AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) capsules, twice a day, for 11 weeks in Period B."},{"id":"OG002","title":"AVP-786-42.63","description":"Participants were enrolled in 1-week double-blind placebo lead-in Period A, and were then randomized to receive AVP-786-42.63 (d6-DM 42.63 mg/Q 4.9 mg) capsules, twice a day, for 11 weeks in Period B."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"type":"PRIMARY","title":"Number of Participants With Treatment Emergent Adverse Events (TEAE) and Serious TEAE","description":"An adverse event (AE) is any untoward medical occurrence or unintended change (eg, physical, psychological, or behavioral), including inter-current illness, that does not necessarily have a causal relationship with the study treatment. A serious adverse event (SAE) is any AE occurring at any dose that results in death, life-threatening experience, persistent or significant disability/incapacity, in-patient hospitalization or prolongation of hospitalization or congenital anomaly/birth defect. TEAEs are all AEs (including serious and non-serious) which started after start of double-blind study drug treatment; or if the event was continuous from baseline and was worsening, serious, study drug related, or resulted in death, discontinuation, interruption or reduction of study therapy.","populationDescription":"Safety population included of all participants who were randomized in the double-blind period B of this study, and took at least one dose of double-blind, randomized study medication. As pre-specified in the Statistical Analysis Plan (SAP), safety data was planned to be collected only for the participants who were randomized in the double-blind period B of this study.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From randomization (Week 2) up to 30 days after last dose of study drug (Up to Week 16)","groups":[{"id":"OG000","title":"Placebo","description":"Participants were enrolled in 1-week double-blind placebo lead-in Period A, and were then randomized to receive AVP-786 matching placebo capsules, twice a day, for 11 weeks in Period B."},{"id":"OG001","title":"AVP-786-18","description":"Participants were enrolled in 1-week double-blind placebo lead-in Period A, and were then randomized to receive AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) capsules, twice a day, for 11 weeks in Period B."},{"id":"OG002","title":"AVP-786-42.63","description":"Participants were enrolled in 1-week double-blind placebo lead-in Period A, and were then randomized to receive AVP-786-42.63 (d6-DM 42.63 mg/Q 4.9 mg) capsules, twice a day, for 11 weeks in Period B."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"57"}]}],"classes":[{"title":"TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"17"}]}]},{"title":"Serious TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"}]}]}]},{"type":"SECONDARY","title":"Change From the End of Period A (Week 1) to Week 10 in the Clinical Global Impression of Severity of Illness (CGIS) Score, as Related to Agitation","description":"The CGIS is an observer-rated scale that measures illness severity. The CGIS-Agitation is a 7-point (1-7) scale (1 = normal, not at all ill; 7 = among the most extremely ill patients) and assesses severity of agitation in this study. Higher scores indicate severe agitation while the lower scores indicate little or no agitation.","populationDescription":"Due to discontinuation of development of the AVP-786 compound, no data was collected and analyzed as planned for this pre-specified secondary efficacy outcome measure as noted in the SAP. Only safety data was collected and analyzed.","reportingStatus":"POSTED","timeFrame":"Week 1 to Week 10","groups":[{"id":"OG000","title":"Placebo","description":"Participants were enrolled in 1-week double-blind placebo lead-in Period A, and were then randomized to receive AVP-786 matching placebo capsules, twice a day, for 11 weeks in Period B."},{"id":"OG001","title":"AVP-786-18","description":"Participants were enrolled in 1-week double-blind placebo lead-in Period A, and were then randomized to receive AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) capsules, twice a day, for 11 weeks in Period B."},{"id":"OG002","title":"AVP-786-42.63","description":"Participants were enrolled in 1-week double-blind placebo lead-in Period A, and were then randomized to receive AVP-786-42.63 (d6-DM 42.63 mg/Q 4.9 mg) capsules, twice a day, for 11 weeks in Period B."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"From randomization (Week 2) up to 30 days after last dose of study drug (Up to Week 16)","description":"Safety population included of all participants who were randomized in the double-blind period B of this study, and took at least one dose of double-blind, randomized study medication. As pre-specified in the SAP, safety data was planned to be collected only for the participants who were randomized in the double-blind period B of this study.","eventGroups":[{"id":"EG000","title":"Placebo","description":"Participants were enrolled in 1-week double-blind placebo lead-in Period A, and were then randomized to receive AVP-786 matching placebo capsules, twice a day, for 11 weeks in Period B.","deathsNumAffected":0,"deathsNumAtRisk":56,"seriousNumAffected":1,"seriousNumAtRisk":56,"otherNumAffected":20,"otherNumAtRisk":56},{"id":"EG001","title":"AVP-786-18","description":"Participants were enrolled in 1-week double-blind placebo lead-in Period A, and were then randomized to receive AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) capsules, twice a day, for 11 weeks in Period B.","deathsNumAffected":1,"deathsNumAtRisk":60,"seriousNumAffected":3,"seriousNumAtRisk":60,"otherNumAffected":14,"otherNumAtRisk":60},{"id":"EG002","title":"AVP-786-42.63","description":"Participants were enrolled in 1-week double-blind placebo lead-in Period A, and were then randomized to receive AVP-786-42.63 (d6-DM 42.63 mg/Q 4.9 mg) capsules, twice a day, for 11 weeks in Period B.","deathsNumAffected":0,"deathsNumAtRisk":57,"seriousNumAffected":2,"seriousNumAtRisk":57,"otherNumAffected":17,"otherNumAtRisk":57}],"seriousEvents":[{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":1,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":1,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Failure to thrive","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":2,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Agitation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]}],"otherEvents":[{"term":"Idiopathic neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":56},{"groupId":"EG001","numAffected":1,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Atrioventricular block","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Sinus bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":1,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":1,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Diverticulum intestinal","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":1,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Tooth loss","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":1,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Facial pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":1,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":1,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Eye infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":1,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Pulpitis dental","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Respiratory tract infection viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":56},{"groupId":"EG001","numAffected":4,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":56},{"groupId":"EG001","numAffected":3,"numAtRisk":60},{"groupId":"EG002","numAffected":2,"numAtRisk":57}]},{"term":"Limb injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Post concussion syndrome","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Scratch","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Skin laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":1,"numAtRisk":60},{"groupId":"EG002","numAffected":2,"numAtRisk":57}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":1,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":1,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Electrocardiogram abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Glycosylated haemoglobin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":1,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Vitamin D decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"White blood cell count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":1,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Iron deficiency","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Bursitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Brain fog","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Coordination abnormal","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":3,"numAtRisk":57}]},{"term":"Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":1,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Hypersomnia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":1,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":1,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Agitation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":1,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Apathy","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":1,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Mutism","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Apnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Hypertensive urgency","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":1,"numAtRisk":57}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (27.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":56},{"groupId":"EG001","numAffected":0,"numAtRisk":60},{"groupId":"EG002","numAffected":0,"numAtRisk":57}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"The study was prematurely terminated due to discontinuation of development of the AVP-786 compound."},"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Clinical Transparency","organization":"Otsuka Pharmaceutical Development & Commercialization, Inc.","email":"smb_clinicaltranspa@otsuka-us.com","phone":"08446878522"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2023-05-15","uploadDate":"2025-04-03T04:56","filename":"Prot_000.pdf","size":10959965},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2024-09-03","uploadDate":"2025-04-03T04:57","filename":"SAP_001.pdf","size":9357135}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-07-25","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2025-04-22","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D003704","term":"Dementia"},{"id":"D000544","term":"Alzheimer Disease"},{"id":"D011595","term":"Psychomotor Agitation"}],"ancestors":[{"id":"D001927","term":"Brain Diseases"},{"id":"D002493","term":"Central Nervous System Diseases"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D019965","term":"Neurocognitive Disorders"},{"id":"D001523","term":"Mental Disorders"},{"id":"D024801","term":"Tauopathies"},{"id":"D019636","term":"Neurodegenerative Diseases"},{"id":"D020820","term":"Dyskinesias"},{"id":"D009461","term":"Neurologic Manifestations"},{"id":"D011596","term":"Psychomotor Disorders"},{"id":"D019954","term":"Neurobehavioral Manifestations"},{"id":"D000096762","term":"Aberrant Motor Behavior in Dementia"},{"id":"D001526","term":"Behavioral Symptoms"}],"browseLeaves":[{"id":"M6904","name":"Dementia","asFound":"Dementia","relevance":"HIGH"},{"id":"M14452","name":"Psychomotor Agitation","asFound":"Agitation","relevance":"HIGH"},{"id":"M3885","name":"Alzheimer Disease","asFound":"Dementia of the Alzheimer's Type","relevance":"HIGH"},{"id":"M5204","name":"Brain Diseases","relevance":"LOW"},{"id":"M5742","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M21836","name":"Neurocognitive Disorders","relevance":"LOW"},{"id":"M14473","name":"Psychotic Disorders","relevance":"LOW"},{"id":"M4815","name":"Mental Disorders","relevance":"LOW"},{"id":"M23002","name":"Tauopathies","relevance":"LOW"},{"id":"M21558","name":"Neurodegenerative Diseases","relevance":"LOW"},{"id":"M22574","name":"Dyskinesias","relevance":"LOW"},{"id":"M12404","name":"Neurologic Manifestations","relevance":"LOW"},{"id":"M14453","name":"Psychomotor Disorders","relevance":"LOW"},{"id":"M21826","name":"Neurobehavioral Manifestations","relevance":"LOW"},{"id":"M3259","name":"Aberrant Motor Behavior in Dementia","relevance":"LOW"},{"id":"M4818","name":"Behavioral Symptoms","relevance":"LOW"},{"id":"T2192","name":"Familial Alzheimer Disease","asFound":"Dementia of the Alzheimer's Type","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BXM","name":"Behaviors and Mental Disorders"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M14652","name":"Quinidine","relevance":"LOW"},{"id":"M236803","name":"Quinidine gluconate","relevance":"LOW"}],"browseBranches":[{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AnArAg","name":"Anti-Arrhythmia Agents"},{"abbrev":"ChanBlk","name":"Channel Blockers"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}